tiprankstipranks
Trending News
More News >
Avalo Therapeutics, Inc. (AVTX)
:AVTX
US Market
Advertisement

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Compare
927 Followers
See the Price Targets and Ratings of:

AVTX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Avalo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$28.98
▲(211.95% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $28.98 with a high forecast of $48.00 and a low forecast of $9.00. The average price target represents a 211.95% change from the last price of $9.29.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.89,10.975384615384614,14.06076923076923,17.146153846153844,20.23153846153846,23.316923076923075,26.40230769230769,29.487692307692306,32.57307692307692,35.65846153846154,38.74384615384615,41.82923076923077,44.91461538461538,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.89,9.512307692307692,11.134615384615383,12.756923076923076,14.37923076923077,16.001538461538463,17.623846153846152,19.246153846153845,20.86846153846154,22.49076923076923,24.113076923076925,25.735384615384614,27.357692307692307,{"y":28.98,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.89,7.975384615384615,8.06076923076923,8.146153846153846,8.231538461538461,8.316923076923077,8.402307692307692,8.487692307692308,8.573076923076924,8.658461538461538,8.743846153846153,8.829230769230769,8.914615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$28.98Lowest Price Target$9.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on AVTX
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Oppenheimer Analyst forecast on AVTX
Oppenheimer
Oppenheimer
$35
Buy
276.75%
Upside
Reiterated
08/11/25
Oppenheimer Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)AVTX continues to execute on its Phase 2 LOTUS trial of AVTX-009, and with cash runway into 2028, we reiterate Outperform.
H.C. Wainwright Analyst forecast on AVTX
H.C. Wainwright
H.C. Wainwright
$15
Buy
61.46%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Iovance Biotherapeutics (NASDAQ: IOVA) and NextCure (NASDAQ: NXTC)
BTIG
$40
Buy
330.57%
Upside
Reiterated
08/07/25
Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy RatingWe also note that LOTUS is expected to involve HS-ABX non-responder criteria, consistent with MLTX's MIRA and VELA trials and in contrast to UCB's (Not Rated) BE HEARD I/II trials; possible implications for UCB discussed in detail below. Mgmt. plans to share LOTUS baseline characteristics data following enrollment completion and expects results to look similar to recent late-stage studies in HS. We see good odds for even better efficacy enabled by AVTX-009's core PK/PD advantages vs. lutikizumab, reviewed in detail HERE. That said, HS remains a large, under-penetrated market with high-growth potential (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s), where we see adequate room for multiple advanced therapies to coexist and be commercially successful.
TR | OpenAI - 4o Analyst forecast on AVTX
TR | OpenAI - 4o
TR | OpenAI - 4o
$9
Hold
-3.12%
Downside
Reiterated
08/06/25
AI Generated ArticleAI Generated Article
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$53.79$19.88
Buy
113.98%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Piper Sandler Analyst forecast on AVTX
Piper Sandler
Piper Sandler
$48
Buy
416.68%
Upside
Reiterated
07/28/25
Piper Sandler Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)
Stifel Nicolaus Analyst forecast on AVTX
Stifel Nicolaus
Stifel Nicolaus
$36
Buy
287.51%
Upside
Reiterated
07/28/25
Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Jefferies Analyst forecast on AVTX
Jefferies
Jefferies
$23
Buy
147.58%
Upside
Initiated
03/25/25
Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment
Wedbush
$18
Buy
93.76%
Upside
Initiated
02/20/25
Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush
Lucid Capital Analyst forecast on AVTX
Lucid Capital
Lucid Capital
$24
Buy
158.34%
Upside
Initiated
12/17/24
Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on AVTX
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
08/15/25
Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Oppenheimer Analyst forecast on AVTX
Oppenheimer
Oppenheimer
$35
Buy
276.75%
Upside
Reiterated
08/11/25
Oppenheimer Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)AVTX continues to execute on its Phase 2 LOTUS trial of AVTX-009, and with cash runway into 2028, we reiterate Outperform.
H.C. Wainwright Analyst forecast on AVTX
H.C. Wainwright
H.C. Wainwright
$15
Buy
61.46%
Upside
Reiterated
08/08/25
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Iovance Biotherapeutics (NASDAQ: IOVA) and NextCure (NASDAQ: NXTC)
BTIG
$40
Buy
330.57%
Upside
Reiterated
08/07/25
Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy RatingWe also note that LOTUS is expected to involve HS-ABX non-responder criteria, consistent with MLTX's MIRA and VELA trials and in contrast to UCB's (Not Rated) BE HEARD I/II trials; possible implications for UCB discussed in detail below. Mgmt. plans to share LOTUS baseline characteristics data following enrollment completion and expects results to look similar to recent late-stage studies in HS. We see good odds for even better efficacy enabled by AVTX-009's core PK/PD advantages vs. lutikizumab, reviewed in detail HERE. That said, HS remains a large, under-penetrated market with high-growth potential (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s), where we see adequate room for multiple advanced therapies to coexist and be commercially successful.
TR | OpenAI - 4o Analyst forecast on AVTX
TR | OpenAI - 4o
TR | OpenAI - 4o
$9
Hold
-3.12%
Downside
Reiterated
08/06/25
AI Generated ArticleAI Generated Article
Berenberg Bank Analyst forecast on AVTX
Unknown Analyst
Berenberg Bank
Not Ranked
Berenberg Bank
$53.79$19.88
Buy
113.98%
Upside
Initiated
08/06/25
Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank
Piper Sandler Analyst forecast on AVTX
Piper Sandler
Piper Sandler
$48
Buy
416.68%
Upside
Reiterated
07/28/25
Piper Sandler Sticks to Its Buy Rating for Avalo Therapeutics (AVTX)
Stifel Nicolaus Analyst forecast on AVTX
Stifel Nicolaus
Stifel Nicolaus
$36
Buy
287.51%
Upside
Reiterated
07/28/25
Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
Jefferies Analyst forecast on AVTX
Jefferies
Jefferies
$23
Buy
147.58%
Upside
Initiated
03/25/25
Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment
Wedbush
$18
Buy
93.76%
Upside
Initiated
02/20/25
Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush
Lucid Capital Analyst forecast on AVTX
Lucid Capital
Lucid Capital
$24
Buy
158.34%
Upside
Initiated
12/17/24
Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

1 Month
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
-3.43%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -3.43% per trade.
3 Months
xxx
Success Rate
2/4 ratings generated profit
50%
Average Return
+17.35%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +17.35% per trade.
1 Year
Success Rate
4/4 ratings generated profit
100%
Average Return
+38.45%
reiterated a buy rating 26 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +38.45% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+38.45%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +38.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
7
5
2
5
9
Buy
0
0
0
0
1
Hold
4
4
5
11
14
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
12
11
9
17
24
In the current month, AVTX has received 10 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 28.98.
Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Next quarter’s earnings estimate for AVTX is -$1.66 with a range of -$1.85 to -$1.25. The previous quarter’s EPS was -$1.92. AVTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.12% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.
Next quarter’s earnings estimate for AVTX is -$1.66 with a range of -$1.85 to -$1.25. The previous quarter’s EPS was -$1.92. AVTX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.12% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.

AVTX Sales Forecast

Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.
Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.23% of the time in the same period. In the last calendar year AVTX has Outperformed its overall industry.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics, Inc.’s 12-month average price target is 28.98.
    What is AVTX’s upside potential, based on the analysts’ average price target?
    Avalo Therapeutics, Inc. has 211.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVTX a Buy, Sell or Hold?
          Avalo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Avalo Therapeutics, Inc.’s price target?
            The average price target for Avalo Therapeutics, Inc. is 28.98. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $48.00 ,the lowest forecast is $9.00. The average price target represents 211.95% Increase from the current price of $9.29.
              What do analysts say about Avalo Therapeutics, Inc.?
              Avalo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of AVTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis